Ahead of its Capital Markets Day on Tuesday, Lonza announced back-to-back partnership deals that cover two Swiss facility customizations and the potential creation of around 415 new jobs once manufacturing is at its peak.
On Monday, Lonza and vaccine biotech Vaxcyte said they are starting a new manufacturing deal to support the production of Vaxcyte’s pneumococcal conjugate vaccines. In a Friday announcement, the Swiss company also said it has expanded its collaboration with an unnamed “major biopharmaceutical partner” to meet its bioconjugate handling and filling needs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.